Design sample · Research links are real. Editorial status, review dates, and change events are illustrative. No independent clinical review is claimed.
Start with the study
The retatrutide phase 2 paper reports a randomized trial of 338 adults, with a primary weight-change endpoint at 24 weeks and follow-up to 48 weeks.
Keep the limits close
A result from one study has a defined population and timeframe. It does not establish current approval, outcomes in other populations, or the complete safety profile.
What comes next?
A maintained overview needs an up-to-date review of subsequent results. This historical reading sample does not claim to provide that review.
PUT IT IN CONTEXT
Retatrutide: the reference
Continue to the source details, limitations, and associated change example.
Open the referenceGo to the source.
- 01
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM et al. · New England Journal of Medicine · 2023